ImmunityBio Stock Surges on Clinical and Commercial Milestones

ImmunityBio completes pivotal bladder cancer trial early, reports 700% revenue growth for Anktiva, and expands global approvals, driving a fivefold stock surge in 2026.

ImmunityBio has successfully completed patient enrollment for a pivotal bladder cancer trial ahead of schedule, a key development that has propelled its share price to a fivefold increase since the start of 2026.

Accelerated Trial Progress and Regulatory Pathway

On February 26, the biotechnology firm finalized recruitment for its Phase 2 study, QUILT-2.005, involving all 366 planned participants. This randomized trial is evaluating the combination of Anktiva with BCG therapy against BCG alone in patients with carcinoma in situ bladder cancer who have not previously received BCG.

According to the company, an interim analysis requested by the U.S. Food and Drug Administration (FDA) demonstrated a statistically significant extension in the duration of response for the group receiving the combination treatment. No relevant safety signals were identified.

ImmunityBio aims to submit a Biologics License Application (BLA) to the FDA by the fourth quarter of 2026, a timeframe that also anticipates additional study results. Regulatory approval would significantly broaden Anktiva's addressable market by extending its use from BCG-refractory cases to the much larger population of BCG-naïve patients.

Financial Performance Fuels Investor Enthusiasm

This clinical advancement follows a period of explosive financial growth. ImmunityBio reported on February 23 that net product revenue for Anktiva reached approximately $113 million for the full year 2025, representing growth of roughly 700% year-over-year. The volume of product sold increased by 750%.

Fourth-quarter net revenue stood at $38.3 million, a sequential increase of 20%. The company's loss per share narrowed to $0.06, surpassing the consensus estimate of a $0.08 loss. This marked the third consecutive quarter of improved earnings.

The financial report triggered a sharp rally in the company's shares. The stock hit an intraday high of $12.28 on February 25 before closing at $11.55, a single-day gain of 17.5%. Since the beginning of the year, the equity has surged from around $2 to over $12 at times, a gain exceeding 500%. Trading volume spiked to over 85 million shares on February 23, more than double the three-month average, as the market capitalization approached $10 to $11 billion.

Global Regulatory Footprint Expands Rapidly

Anktiva's approved status has seen rapid international expansion in early 2026:

• European Union: The European Commission granted conditional marketing authorization in February for Anktiva plus BCG in BCG-refractory bladder cancer across all 27 member states, plus Iceland, Norway, and Liechtenstein.
• Saudi Arabia: The Saudi Food and Drug Authority (SFDA) approved an accelerated authorization for bladder cancer in January. In a global first, the jurisdiction also granted a conditional approval for Anktiva's use in metastatic non-small cell lung cancer in combination with checkpoint inhibitors.
• United Kingdom: The Medicines and Healthcare products Regulatory Agency (MHRA) granted approval in July 2025.
• United States: The initial FDA approval was received in April 2024.

Anktiva is now approved for use in 33 countries across four major jurisdictions.

Broad Pipeline Extends Beyond Bladder Cancer

The company's clinical development pipeline includes several parallel programs targeting other cancers:

• The single-arm QUILT-3.055 study in lung cancer has been completed. Following Saudi Arabia's accelerated approval, discussions with the FDA are planned for 2026.
• An expanded access program for recombinant BCG is underway at U.S. sites with 580 patients enrolled. A meeting with the FDA regarding a potential regulatory submission is scheduled for March.
• A CAR-NK cell therapy is being investigated in a Phase 2 study for indolent lymphomas without chemotherapy.
• Additional studies are ongoing in pancreatic cancer, triple-negative breast cancer, glioblastoma, and chemotherapy-induced lymphopenia.

Strategic Position for Sustained Growth

The timely completion of the QUILT-2.005 trial represents a critical inflection point for ImmunityBio's commercial strategy. A successful approval in the BCG-naïve setting would substantially increase the drug's market opportunity in bladder cancer. Concurrently, the company is preparing commercial launches in Europe and the Middle East. The execution of these regulatory milestones and the continued path toward profitability remain the focal points for investors monitoring the company's progress in 2026.